Arrhythmia recurrence
48 of 53 (91%) patients completed 1 year follow up, with an average follow up length of 11.5 ± 1.9 months. Follow up length was similar between the two groups. Overall 6 patients (11%) had long term continuous monitoring with an implantable device (PPM, ICD, or ILR), equally distributed between groups. The remaining patients underwent 1 or 2-week ambulatory event monitoring at 3, 6, and 12 months post-procedure (average 2.3 ± 1.1 monitors). 87% of patients were maintained on an anti-arrhythmic medication (Amiodarone, Dronedarone, or Flecainide) for one month post-procedure, and 85% of patients were continued on long term beta-blocker and/or calcium channel blocker therapy (Table 1). One year arrhythmia-free survival was similar between the atrial-paced and ventricular-paced patients (78% vs 67%, p = 0.31) (Figure 3).